Wuhan YZY Biopharma Co., Ltd. announced that, the first patient has recently been enrolled in a pivotal Phase III registrational clinical trial of M701, a bispecific antibody (?BsAb?) drug candidate dually targeting epithelial cell adhesion molecule (?EpCAM?) and cluster of differentiation 3 (?CD3?) independently developed by the Company. The MA Study aims to evaluate the efficacy and safety of M701 through intraperitoneal infusion compared to peritoneal drainage in the treatment of patients with malignant ascites (?MA?) caused by advanced epithelial solid tumors. If successful, the MA Study will be used to support the marketing approval application of M701 for the first indication in China.